Hosted on MSN

CVKD: Designing phase 3 trial for CAD-1005 in HIT

Planning for Phase 3 Registration Trial of CAD-1005 in HIT On April 30, 2026, Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) announced an ‘End-of-Phase 2’ meeting with the U.S. Food and Drug ...
New Atlas

USA's new tallest timber tower halted mid-build, future uncertain

An ambitious new timber skyscraper that's set to become the tallest of its kind in the United States – and indeed the world – has hit a snag. The building has been under construction in Milwaukee, ...
Nasdaq

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of ...
manilatimes

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 ...

Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in ...